News Release

share on google plus
Text size
view with small font size
view with medium font size
view with large font size

Kyowa Hakko Kirin News Releases 2017

December 11, 2017
Kyowa Hakko Kirin Announces Results of Phase 3 Clinical Study of Mogamulizumab (KW-0761) in Patients with Cutaneous T-cell Lymphoma at the American Society of Hematology 2017PDF file:New window opens(193KB)
December 4, 2017
Ultragenyx and Kyowa Kirin Announce Positive 48-Week Data from Adult Phase 3 Study of Burosumab (KRN23) in X-Linked HypophosphatemiaPDF file:New window opens(179KB)
November 30, 2017
Kyowa Hakko Kirin Submits the Partial Change Approval Application of Mogamulizumab in JapanPDF file:New window opens(80KB)
November 28, 2017
Kyowa Hakko Kirin Announces FDA Acceptance for Filing and Priority Review Designation of Mogamulizumab's Biologics License ApplicationPDF file:New window opens(96KB)
November 28, 2017
Ardelyx and Kyowa Hakko Kirin Announce License Agreement for Tenapanor for Cardiorenal Diseases in JapanPDF file:New window opens(188KB)
November 6, 2017
Kyowa Hakko Kirin Presented Results of Phase II Study of Bardoxolone Methyl in Japan at the ASN Kidney Week 2017PDF file:New window opens(107KB)
November 6, 2017
Kyowa Hakko Kirin Presented Results of Japan Phase III Clinical Study of Evocalcet at Kidney Week 2017 of the American Society of NephrologyPDF file:New window opens(75KB)
November 1, 2017
Ultragenyx and Kyowa Hakko Kirin Announce FDA Not Currently Planning to Hold Advisory Committee Meeting for Burosumab Biologics License ApplicationPDF file:New window opens(186KB)
October 31, 2017
Concerning an Announcement by Kirin Holdings Company, LimitedPDF file:New window opens(59KB)
October 30, 2017
Kyowa Hakko Kirin Announces Initiation of the Phase III Clinical Study of KHK7580 (evocalcet) for Hypercalcemia in Patients with Parathyroid Carcinoma or Primary HyperparathyroidismPDF file:New window opens(140KB)
October 27, 2017
Kyowa Hakko Kirin Announces Marketing Authorisation Application for Mogamulizumab Validated by European Medicines AgencyPDF file:New window opens(114KB)
October 26, 2017
New window opensAnnouncement of Consolidated Financial Results Fiscal 2017 Third Quarter
October 26, 2017
Matters Concerning Voluntary Adoption ofInternational Financial Reporting Standards (IFRS)PDF file:New window opens(34KB)
October 17, 2017
Kyowa Hakko Kirin Announces the Intent to File Istradefylline (KW-6002) for Parkinson's Disease with the US FDAPDF file:New window opens(76KB)
October 10, 2017
Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and Priority Review Designation of Burosumab's Biologics License ApplicationPDF file:New window opens(165KB)
October 6, 2017
Kyowa Hakko Kirin Announces Discontinuation for Developing ARQ 197 (Tivantinib)PDF file:New window opens(122KB)
September 29, 2017
Notice Concerning Share Transfer Associated with Change in a Consolidated CompanyPDF file:New window opens(50KB)
September 14, 2017
Kyowa Hakko Kirin Acquired Approval for Additional Formulation of ACOALAN® in JapanPDF file:New window opens(123KB)
September 12, 2017
Ultragenyx and Kyowa Hakko Kirin Announce Additional Burosumab Data in X-Linked Hypophosphatemia (XLH) and Tumor-Induced Osteomalacia (TIO) at ASBMRPDF file:New window opens(175KB)
August 31, 2017
Announcement of submission of supplemental new drug application (NDA) for the addition of a new 0.5mg dose of the transdermal, long-acting pain relief patch FENTOS® TAPE (development code: HFT-290)PDF file:New window opens(123KB)
August 25, 2017
US Food and Drug Administration Grants Breakthrough Therapy Designation for Mogamulizumab for the treatment of Mycosis Fungoides and Sézary SyndromePDF file:New window opens(96KB)
August 24, 2017
Ultragenyx and Kyowa Hakko Kirin Announce Submission of Burosumab's Biologics License Application in the USPDF file:New window opens(163KB)
August 24, 2017
Kyowa Hakko Kirin and Kyowa Kirin International Announce Burosumab Data Presentations at ASBMR 2017 Annual MeetingPDF file:New window opens(147KB)
July 28, 2017
New window opensAnnouncement of Consolidated Financial Results Fiscal 2017 Second Quarter
July 28, 2017
Kyowa Hakko Kirin and Kyowa Kirin International Announce Regulatory Updates for Burosumab in the US and EUPDF file:New window opens(134KB)
June 30, 2017
Kyowa Hakko Kirin Announces Initiation of Phase 3 Study in Japan of Mogamulizumab in Patients with HTLV-1 Associated MyelopathyPDF file:New window opens(139KB)
June 22, 2017
Partnership Agreement for a Gel Formulation of Dovobet® in Japan: Treatment for Psoriasis VulgarisPDF file:New window opens(130KB)
May 22, 2017
FUJIFILM KYOWA KIRIN BIOLOGICS Announces Marketing Authorisation Application for FKB327 Accepted for Review by European Medicines AgencyPDF file:New window opens(58KB)
April 27, 2017
New window opensAnnouncement of Consolidated Financial Results Fiscal 2017 First Quarter
April 27, 2017
Kyowa Hakko Kirin Submits Application for Approval of Evocalcet (KHK7580) for Secondary Hyperparathyroidism in Maintenance Dialysis Patients in JapanPDF file:New window opens(111KB)
April 24, 2017
Kyowa Hakko Kirin Announces Initiation of Global Phase 3 Study of KHK4827 (Brodalumab) in Patients with Axial Spondyloarthritis (axSpA)PDF file:New window opens(107KB)
April 19, 2017
Ultragenyx, Kyowa Hakko Kirin and Kyowa Kirin International Announce Positive 24-Week Data
from Adult Phase 3 Study of Burosumab (KRN23) in X-Linked Hypophosphatemia
PDF file:New window opens(177KB)
April 7, 2017
Kyowa Hakko Kirin Announces Positive Results of the Phase 3 Clinical Study of Mogamulizumab (KW-0761) in Patients with Cutaneous T-cell LymphomaPDF file:New window opens(115KB)
April 6, 2017
Ultragenyx and Kyowa Kirin International Announce Positive Data from Paediatric Phase 2 Studies of Burosumab (KRN23) in X-Linked HypophosphatemiaPDF file:New window opens(212KB)
March 31, 2017
Matters concerning controlling shareholdersPDF file:New window opens(44KB)
March 27, 2017
Kyowa Hakko Kirin Announces Top-Line Results of Japanese Phase 3 Clinical Study of ARQ197 (tivantinib) in Hepatocellular CarcinomaPDF file:New window opens(130KB)
March 24, 2017
Kyowa Hakko Kirin Enters Agreement with AstraZeneca for Development and Commercialisation of Benralizumab in AsiaPDF file:New window opens(118KB)
March 23, 2017
Notice regarding allotment of stock acquisition rights (stock compensation-type stock options)PDF file:New window opens(25KB)
March 3, 2017
The UK High Court of Justice (Patents) Rules in Fujifilm Kyowa Kirin Biologics' Favor on Rheumatoid Arthritis, Psoriasis and Psoriatic Arthritis Dosing Regimens for Adalimumab are Obvious and UnpatentablePDF file:New window opens(80KB)
February 17, 2017
Notice regarding stock acquisition rights for stock compensation-type stock optionsPDF file:New window opens(21KB)
February 17, 2017
Notice regarding the revision of the remuneration system for officersPDF file:New window opens(20KB)
January 31, 2017
New window opensAnnouncement of Consolidated Financial Results Fiscal 2016
January 31, 2017
Notice of Recording of Extraordinary Losses in Non-consolidated Financial ResultsPDF file:New window opens(12KB)
January 31, 2017
Kyowa Hakko Kirin Establishes Kyowa Kirin Frontier Co., Ltd.PDF file:New window opens(21KB)
January 31, 2017
Kyowa Hakko Kirin Announces Top-Line Results of Phase 3 Clinical Study of KHK7580 with Secondary Hyperparathyroidism in JapanPDF file:New window opens(109KB)
January 5, 2017
Ultragenyx and Kyowa Kirin International Announce Marketing Authorisation Application for KRN23 Filed and Accepted for Review by European Medicines AgencyPDF file:New window opens(106KB)

Get Adobe® Reader®You need Adobe® Reader® to view these documents.
Download Adobe® Reader® of Adobe Systems here.



To Page Top